CRBU vs NKTX
CRBU: A clinical-stage CRISPR genome-editing company developing off-the-shelf allogeneic CAR-T cell therapies for hematologic cancers. NKTX: Nkarta is a clinical-stage biotechnology company pioneering off-the-shelf, engineered natural killer (NK) cell therapies to treat autoimmune diseases by depleting pathogenic B cells.
Side-by-side fundamentals
| Metric | CRBU | NKTX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $0.4812 | $2.22 | |
| Market cap | $52M | $159M | |
| Net margin FY2025, SEC XBRL | -1327.4% | n/a | |
| Operating margin FY2025, SEC XBRL | -1329.4% | n/a | |
| ROE FY2025, SEC XBRL | -121.2% | -33.3% | NKTX higher |
| ROA FY2025, SEC XBRL | -84.5% | -25.8% | NKTX higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-09-03 | +13.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -7.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.79 | 1.25 | |
| 1-year return as of 2026-10-08 close | -82.0% | +6.2% | NKTX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.